maladies – Remboursement des médicaments contre la maladie dégénérative MCL

This written question asks about the reimbursement conditions for drugs treating the degenerative disease MCL. It seeks clarification on accessibility and financial coverage for patients. The question affects patients with MCL, healthcare providers, and pharmaceutical companies involved in treating this condition.